These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26654211)

  • 1. Quantifying and qualifying the preventive effects of acute-phase cognitive therapy: Pathways to personalizing care.
    Jarrett RB; Minhajuddin A; Vittengl JR; Clark LA; Thase ME
    J Consult Clin Psychol; 2016 Apr; 84(4):365-76. PubMed ID: 26654211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up.
    Jarrett RB; Thase ME
    Contemp Clin Trials; 2010 Jul; 31(4):355-77. PubMed ID: 20451668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of longitudinal outcomes after unstable response to acute-phase cognitive therapy for major depressive disorder.
    Vittengl JR; Clark LA; Thase ME; Jarrett RB
    Psychotherapy (Chic); 2015 Jun; 52(2):268-77. PubMed ID: 25985046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial Steps to inform selection of continuation cognitive therapy or fluoxetine for higher risk responders to cognitive therapy for recurrent major depressive disorder.
    Vittengl JR; Anna Clark L; Thase ME; Jarrett RB
    Psychiatry Res; 2017 Jul; 253():174-181. PubMed ID: 28388454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stable remission and recovery after acute-phase cognitive therapy for recurrent major depressive disorder.
    Vittengl JR; Clark LA; Thase ME; Jarrett RB
    J Consult Clin Psychol; 2014 Dec; 82(6):1049-59. PubMed ID: 25045908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo.
    Jarrett RB; Minhajuddin A; Gershenfeld H; Friedman ES; Thase ME
    JAMA Psychiatry; 2013 Nov; 70(11):1152-60. PubMed ID: 24005123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.
    Thase ME; Gelenberg A; Kornstein SG; Kocsis JH; Trivedi MH; Ninan P; Li T; Pedersen R; Keller M
    J Psychiatr Res; 2011 Mar; 45(3):412-20. PubMed ID: 20801464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder.
    Perlis RH; Nierenberg AA; Alpert JE; Pava J; Matthews JD; Buchin J; Sickinger AH; Fava M
    J Clin Psychopharmacol; 2002 Oct; 22(5):474-80. PubMed ID: 12352270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases.
    Keller MB; Trivedi MH; Thase ME; Shelton RC; Kornstein SG; Nemeroff CB; Friedman ES; Gelenberg AJ; Kocsis JH; Dunner DL; Dunlop BW; Hirschfeld RM; Rothschild AJ; Ferguson JM; Schatzberg AF; Zajecka JM; Pedersen R; Yan B; Ahmed S; Schmidt M; Ninan PT
    Biol Psychiatry; 2007 Dec; 62(12):1371-9. PubMed ID: 17825800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal social-interpersonal functioning among higher-risk responders to acute-phase cognitive therapy for recurrent major depressive disorder.
    Vittengl JR; Clark LA; Thase ME; Jarrett RB
    J Affect Disord; 2016 Jul; 199():148-56. PubMed ID: 27104803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression.
    Gelenberg AJ; Trivedi MH; Rush AJ; Thase ME; Howland R; Klein DN; Kornstein SG; Dunner DL; Markowitz JC; Hirschfeld RM; Keitner GI; Zajecka J; Kocsis JH; Russell JM; Miller I; Manber R; Arnow B; Rothbaum B; Munsaka M; Banks P; Borian FE; Keller MB
    Biol Psychiatry; 2003 Oct; 54(8):806-17. PubMed ID: 14550680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defined symptom-change trajectories during acute-phase cognitive therapy for depression predict better longitudinal outcomes.
    Vittengl JR; Clark LA; Thase ME; Jarrett RB
    Behav Res Ther; 2016 Dec; 87():48-57. PubMed ID: 27591917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do comorbid social and other anxiety disorders predict outcomes during and after cognitive therapy for depression?
    Vittengl JR; Clark LA; Smits JAJ; Thase ME; Jarrett RB
    J Affect Disord; 2019 Jan; 242():150-158. PubMed ID: 30176494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.
    Kornstein SG; Kocsis JH; Ahmed S; Thase M; Friedman ES; Dunlop BW; Yan B; Pedersen R; Ninan PT; Li T; Keller M
    Int Clin Psychopharmacol; 2008 Nov; 23(6):357-63. PubMed ID: 18854724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive-behavioral therapy to prevent relapse in pediatric responders to pharmacotherapy for major depressive disorder.
    Kennard BD; Emslie GJ; Mayes TL; Nightingale-Teresi J; Nakonezny PA; Hughes JL; Jones JM; Tao R; Stewart SM; Jarrett RB
    J Am Acad Child Adolesc Psychiatry; 2008 Dec; 47(12):1395-404. PubMed ID: 18978634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reducing relapse in depressed outpatients with atypical features: a pilot study.
    Jarrett RB; Kraft D; Schaffer M; Witt-Browder A; Risser R; Atkins DH; Doyle J
    Psychother Psychosom; 2000; 69(5):232-9. PubMed ID: 10965287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life after response to acute-phase cognitive therapy for recurrent depression.
    Vittengl JR; Jha MK; Minhajuddin A; Thase ME; Jarrett RB
    J Affect Disord; 2021 Jan; 278():218-225. PubMed ID: 32971314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of preventive cognitive therapy in recurrent depression: a 5.5-year follow-up study.
    Bockting CL; Spinhoven P; Wouters LF; Koeter MW; Schene AH;
    J Clin Psychiatry; 2009 Dec; 70(12):1621-8. PubMed ID: 20141705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive reactivity, dysfunctional attitudes, and depressive relapse and recurrence in cognitive therapy responders.
    Jarrett RB; Minhajuddin A; Borman PD; Dunlap L; Segal ZV; Kidner CL; Friedman ES; Thase ME
    Behav Res Ther; 2012 May; 50(5):280-6. PubMed ID: 22445946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.